Dutch biopharmaceutical company Prosensa, developer of the experimental drug drisapersen and other experimental compounds for Duchenne muscular dystrophy (DMD), will update the investor community via a Thursday, Jan. 16, 2014, presentation at the J.P. Morgan Healthcare Conference in San Francisco. The presentation will be webcast at 10 a.m. Pacific time/1 p.m. Eastern time.
On Tuesday, Jan. 21, at 8 a.m. Eastern time, Prosensa will conduct a separate webinar for DMD patients and families.
Be sure to stay with Quest for the latest updates. Check back in the coming days for recaps on the Prosensa/drisapersen webcasts.